KARD Stock Analysis: Kardigan, Common Stock | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.142m USD | 12M Return: 4.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.8M
Warnings
Tailwinds
No distinct edge detected
Seasonality 0 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kardigan, Inc. (NASDAQ: KARD) is a Princeton, New Jersey-based biopharmaceutical company founded in 2023 (formerly known as EnCarda, Inc. until December 2024) that develops medicines targeting the underlying pathophysiology of cardiovascular diseases, with a particular focus on primary and secondary cardiomyopathies that lead to heart failure. The company operates a proprietary R&D platform combining AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking, and incorporates Prolaios cardiovascular data collection and analytics platform, which features FDA-cleared algorithms. Kardigan expands its pipeline through strategic in-licensing and acquisitions, and serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers within the cardiology sector.
As a clinical-stage biotechnology company in the healthcare sector, Kardigan operates within a segment of the biopharmaceutical industry where development cycles are typically long and capital-intensive, with revenue often dependent on partnerships, licensing agreements, or future commercialization of therapeutics rather than near-term product sales. Cardiovascular disease represents one of the largest therapeutic areas by patient population and global mortality burden, which has historically attracted significant R&D investment from both large pharmaceutical companies and venture-backed biotechs.
- Heart failure pipeline readouts drive near-term stock catalysts
- Strategic in-licensing and acquisitions expand cardiovascular drug portfolio
- AI-driven R&D platform with Prolaio accelerates clinical development efficiency
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA 41.67 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.43 > 3% & CFO -151.1m > Net Income -191.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.42 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (NaN) vs prev NaN% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.77 (Total Current Assets 298.1m - Total Current Liabilities 31.7m) / Total Assets 348.2m |
| B: -0.97 (Retained Earnings -337.2m / Total Assets 348.2m) |
| C: -0.98 (EBIT TTM -201.8m / Avg Total Assets 205.9m) |
| D: -0.46 (Book Value of Equity -300.6m / Total Liabilities 648.8m) |
| Altman-Z'' = -5.21 = D |
As of July 08, 2026, the stock is trading at USD 23.83 with a total of 272,235 shares traded. Over the past week, the price has changed by -7.99%, over one month by +4.66%, over three months by +4.66% and over the past year by +4.66%.
Current recommended Stop Loss: 22.60 (which is 5.2% below the current price).
Kardigan, Common Stock has no consensus analysts rating.
Revenue TTM = 0.0 USD
EBIT TTM = -201.8m USD
EBITDA TTM = -196.0m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 13.9m USD (Leases only: 13.9m)
Net Debt = -67.6m USD (calculated: Debt 13.9m - CCE 81.5m)
Enterprise Value = 2.07b USD (2.14b + Debt 13.9m - CCE 81.5m)
Interest Coverage Ratio = unknown (Ebit TTM -201.8m / Interest Expense TTM 0.0)
EV/FCF = -13.15x (Enterprise Value 2.07b / FCF TTM -157.7m)
FCF Yield = -7.60% (FCF TTM -157.7m / Enterprise Value 2.07b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 5.96 (Enterprise Value 2.07b / Total Assets 348.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 13.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -159.5m (EBIT -201.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.42 (Total Current Assets 298.1m / Total Current Liabilities 31.7m)
Debt / Equity = -0.05 (negative equity) (Debt 13.9m / totalStockholderEquity, last quarter -300.6m)
Debt / EBITDA = 0.35 (negative EBITDA) (Net Debt -67.6m / EBITDA -196.0m)
Debt / FCF = 0.43 (negative FCF - burning cash) (Net Debt -67.6m / FCF TTM -157.7m)
Total Stockholder Equity = -250.3m (last fiscal year from totalStockholderEquity)
RoA = -93.24% (Net Income -191.9m / Total Assets 348.2m)
RoE = 76.67% (negative equity) (Net Income TTM -191.9m / Total Stockholder Equity -250.3m)
RoCE = -63.77% (EBIT -201.8m / Capital Employed (Total Assets 348.2m - Current Liab 31.7m))
RoIC = -50.38% (negative operating profit) (NOPAT -159.5m / Invested Capital 316.5m)
WACC = 0.0% (E(2.14b)/V(2.16b) * Re(0.0%) + D(13.9m)/V(2.16b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.29% (= Risk Free + ERP)
[DCF] Fair Price = unknown (Cash Flow -157.7m)
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0